aTyr Pharma (LIFE)
(Delayed Data from NSDQ)
$1.73 USD
-0.03 (-1.70%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.74 +0.01 (0.58%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
aTyr Pharma, Inc. [LIFE]
Reports for Purchase
Showing records 61 - 80 ( 174 total )
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
KOL Highlights Need in Sarcoidosis Ahead of ATYR1923''s Data in 3Q2021
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
The Final Setup; KOL Perspective Ahead of Critical Phase 1b/2a Sarcoidosis Data in 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Results; Exciting Pipeline Developments While Waiting For Top-Line Data In Sarcoidosis in 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Update - Sarcoidosis Data Expected in 3Q21, NRP Antibody IND in 4Q21
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
AACR Highlights ATYR2810''s Mono and Combo Potential in TNBC and NSCLC
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
2020 Results; Clinical Validation for ATYR1923 Continues Ahead of Sarcoidosis Data in 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 - Sarcoidosis Data in 3Q2021 Will Be a Major Value-inflection Point
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
COVID Patients'' Biomarker Data Validate ATYR1923''s MOA-Raising PT to $20
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
ATYR1923 Delivers Key MoA''s Validation in the Clinic Ahead of Sarcoidosis Results in 3Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
New Data Highlight Why NRP2 Is a Cancer Target Not to Be Ignored
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
ATYR1923 Positioned Well for 2021 and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: aTyr Pharma, Inc.
Industry: Medical - Biomedical and Genetics
Another Milestone Reached in Steps to Get 1923 Approved in Japan for ILDs
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z